AbbVie Inc. ($ABBV) Stock Forecast: Down 5.2% Today

What is AbbVie Inc.?

ABBV is a pharmaceutical company recognized for its immunology drugs, particularly Skyrizi, in a competitive market environment.

Why is AbbVie Inc. going down?

ABBV stock is down 5.2% on Mar 18, 2026 19:56

• ABBV stock saw a 5% drop post the FDA approval of J&J's Icotyde, a new oral plaque psoriasis treatment, creating direct competition with AbbVie's Skyrizi.
• Analysts predict a 23% increase in Skyrizi sales by FY2026, notwithstanding the competition, showcasing some strength in AbbVie's market position.
• The decrease in ABBV stock value can be linked to worries regarding Icotyde's impact on Skyrizi's market presence, compounded by ongoing challenges from Humira's loss of exclusivity and falling aesthetics segment sales.
• With Icotyde's approval as a convenient oral option with high effectiveness compared to injectables, it presents a significant challenge to AbbVie's dominance in the psoriasis treatment sector, leading to a pessimistic outlook on ABBV stock.

ABBV Price Chart

ABBV Technical Analysis

ABBV News

J&J Gets FDA Nod for Plaque Psoriasis Pill Positioned to Compete With Injectables

Johnson & Johnson has received FDA approval for Icotyde, a once-daily pill for moderate-to-severe plaque psoriasis, which is positioned to compete with injectable treatments. Developed in partnership with Protagonist Therapeutics, this oral medication targets the IL-23 receptor, similar to some injectables, and has shown superior efficacy compared to a placebo and Bristol Myers Squibb's oral Sotyktu in clinical trials. J&J projects Icotyde could achieve over $5 billion in peak annual revenue and is also being developed for other immunological indications.

https://medcitynews.com/2026/03/jj-gets-fda-nod-for-plaque-psoriasis-pill-positioned-to-compete-with-injectables/

AbbVie (ABBV) Stock Drops 5% After FDA Approves J&J’s Competing Psoriasis Drug

AbbVie (ABBV) stock dropped almost 5% after the FDA approved Johnson & Johnson's Icotyde, a new oral plaque psoriasis treatment, posing a challenge to AbbVie's Skyrizi. Despite this new competition, analysts still expect Skyrizi's sales to grow by 23% by FY2026. The stock's technical indicators appear bearish, exacerbated by ongoing challenges from Humira's loss of exclusivity and declining aesthetic segment sales.

https://coincentral.com/abbvie-abbv-stock-drops-5-after-fda-approves-jjs-competing-psoriasis-drug/

J&J, Protagonist's 'game-changer' once-daily psoriasis pill Icotyde nabs FDA approval

The FDA has approved Icotyde (icotrokinra), a once-daily pill developed by Johnson & Johnson and Protagonist Therapeutics, for moderate-to-severe plaque psoriasis in patients aged 12 and older. This approval marks a significant advancement as Icotyde is the first targeted oral peptide for psoriasis, offering a convenient alternative to injectable biologics with "biologic-level efficacy." Analysts project Icotyde could achieve peak sales between $5.5 billion and $7.5 billion, and the partners are exploring its potential for other immunology indications.

https://www.fiercepharma.com/pharma/jj-protagonists-game-changer-once-daily-psoriasis-pill-icotyde-nabs-fda-approval

J&J’s psoriasis pill to rival AbbVie’s Skyrizi (JNJ:NYSE)

Johnson & Johnson's newly approved psoriasis pill, Icotyde, is expected to compete with AbbVie's immunology drug Skyrizi. Following this news, AbbVie's stock fell by approximately 4%. The competition poses a challenge to Skyrizi, a key immunology blockbuster for AbbVie.

https://seekingalpha.com/news/4565887-jjs-psoriasis-pill-rival-abbvies-skyrizi

AbbVie Inc Stock (ABBV) Moved Down by 4.60% on Mar 18: A Full Analysis

AbbVie Inc (ABBV) stock fell by 4.60% on March 18, driven by ongoing pressure from Humira biosimilar competition, weakness in its aesthetics business, and recent insider share sales. Technical indicators suggest a correction and weakening trend momentum. Despite some positive developments in its pipeline, these factors fueled negative sentiment amongst investors.

https://www.tradingkey.com/news/Market-Movers/261694905-market-movers-abbv-20260318

Trending Today

Blink Charging Co. ($BLNK) Stock Forecast: Up 9.1% Today

Teladoc Health Inc. ($TDOC) Stock Forecast: Up 5.6% Today

Opendoor Technologies Inc. ($OPEN) Stock Forecast: Up 5.1% Today

Repligen Corporation ($RGEN) Stock Forecast: Up 5.7% Today

Baxter International Inc. ($BAX) Stock Forecast: Up 5.1% Today

Raymond James Financial Inc. ($RJF) Stock Forecast: Up 2.0% Today

Charles Schwab Corporation (The) ($SCHW) Stock Forecast: Up 1.3% Today

Beyond Meat Inc. ($BYND) Stock Forecast: Down 10.3% Today

Jetblue Airways Corporation ($JBLU) Stock Forecast: Up 6.5% Today

CleanSpark Inc ($CLSK) Stock Forecast: Up 5.9% Today

AbbVie Inc. Price History

18.02.2026 - ABBV Stock was down 5.2%

• ABBV stock saw a 5% drop post the FDA approval of J&J's Icotyde, a new oral plaque psoriasis treatment, creating direct competition with AbbVie's Skyrizi.
• Analysts predict a 23% increase in Skyrizi sales by FY2026, notwithstanding the competition, showcasing some strength in AbbVie's market position.
• The decrease in ABBV stock value can be linked to worries regarding Icotyde's impact on Skyrizi's market presence, compounded by ongoing challenges from Humira's loss of exclusivity and falling aesthetics segment sales.
• With Icotyde's approval as a convenient oral option with high effectiveness compared to injectables, it presents a significant challenge to AbbVie's dominance in the psoriasis treatment sector, leading to a pessimistic outlook on ABBV stock.

18.02.2026 - ABBV Stock was down 5.0%

• The current downward movement in ABBV stock may be linked to significant reductions in holdings by Wilmington Savings Fund Society FSB, offloading 26,080 shares in the third quarter, as well as insider selling of substantial stakes.
• Despite AbbVie surpassing quarterly expectations and offering robust FY2026 guidance, the selling activities by major institutions and insiders could have triggered investor apprehensions, contributing to the current bearish trend.
• Information regarding Johnson & Johnson's FDA approval for a new oral psoriasis pill, Icotyde, creating competition in the psoriasis market, might have also impacted investor confidence in AbbVie's future market share and revenue potential.

18.02.2026 - ABBV Stock was down 5.2%

• Wilmington Savings Fund Society FSB notably decreased its stake in AbbVie Inc., selling off a significant number of shares, which might reflect a lack of confidence in the company's future.
• Despite AbbVie's outperformance in the last quarter and positive guidance for FY2026, concerns raised by a business health analysis regarding sluggish sales growth and declining financial metrics might have driven the bearish movement.
• The high payout ratio of 293.22%, resulting from a quarterly dividend of $1.73 per share, may have added to investor worries, particularly as insiders in leadership positions were observed selling portions of their shares.
• Danske Bank A S's substantial investment in AbbVie Inc. stands in contrast, potentially indicating divergent views on the stock's performance and future prospects.

18.02.2026 - ABBV Stock was down 5.4%

• AbbVie's stock experienced a significant 4.60% decline on March 18, driven by various factors including:
• Intense competition: Approval of a new oral peptide for psoriasis poses a direct threat to AbbVie's Skyrizi, impacting investor sentiment negatively.
• Biosimilar competition: Ongoing pressure from biosimilar competition for its blockbuster drug Humira continues to weigh on AbbVie's stock performance.
• Weakness in aesthetics business: Challenges in AbbVie's aesthetics business segment also contributed to the bearish movement of the stock.
• Despite some positive developments in AbbVie's pipeline, the combination of these factors led to a correction and weakening trend momentum in the stock price.
• The approval of a new drug by the FDA and its potential as a blockbuster drug with significant sales projections added further pressure on AbbVie's stock, highlighting the competitive landscape in the pharmaceutical industry.

28.09.2025 - ABBV Stock was up 0.0%

• AbbVie's recent market upturn is linked to positive market expectations for its upcoming Q3 earnings, with a particular focus on the growth of Skyrizi and Rinvoq.
• Market sentiment remains optimistic about AbbVie's future prospects despite analyst predictions of an earnings decrease, driven by the success of its leading drugs.
• Although the stock saw a slight decline compared to the overall market recently, the company has demonstrated significant growth of over 30% in the last six months, led by robust sales and product efficacy.
• Investors are considering AbbVie as a favorable investment option, undeterred by some doubts from financial analysts, given the company's strong track record and growth potential in key therapeutic areas.

05.00.2026 - ABBV Stock was down 2.6%

• Today's bearish movement in AbbVie's stock price can be attributed to several factors:
• Despite strong Q3 earnings and dividend increases, the reduction in holdings by institutional investors like Railway Pension Investments Ltd and Commonwealth Equity Services LLC may have signaled concerns about the company's future growth prospects.
• The $100 million upfront investment in the trispecific lung cancer drug ZG006, while positioning AbbVie to challenge competitors like Amgen, might have raised investor worries about the high costs and risks associated with drug development.
• The upcoming presentation at the J.P. Morgan Healthcare Conference could have led to profit-taking by some traders who may have been expecting more significant announcements or guidance from the management.
• The overall market sentiment towards pharmaceutical companies and healthcare stocks today might have also played a role in the bearish movement of AbbVie's stock, as investors may be rotating their portfolios based on sector performance and economic outlook.

04.01.2026 - ABBV Stock was down 8.6%

• AbbVie surpassed analyst estimates with its financial performance in Q4 2025, including strong revenue figures and a notable showing by Humira.
• Despite the optimistic earnings report and an increased profit forecast for 2026, the stock saw a minor decline, potentially influenced by investors taking profits following recent positive developments.
• Market response indicates that notwithstanding the company's positive outlook and solid performance, investors may have held elevated expectations or concerns regarding the future earnings impact of Humira's patent expiration.
• The slight drop in the stock price might also be linked to general market conditions or specific challenges within the pharmaceutical sector affecting investor sentiment.

01.09.2025 - ABBV Stock was up 6.3%

• The bullish trend in AbbVie's stock is linked to the company's announcement about seeking FDA approval for tavapadon, a potential treatment for Parkinson's disease. This development signifies advancement in the company's pipeline and hints at possible future revenue growth.
• While some investors showed bearish options activity, this viewpoint may be a short-term reaction, influenced by market fluctuations or individual strategies, rather than reflecting the overall optimistic outlook for AbbVie.
• AbbVie's shift beyond its successful drug Humira, with promising products like Skyrizi and Rinvoq, alongside its expansion into oncology and neuroscience fields, is likely instilling investor confidence and spurring the positive momentum in the stock.

01.09.2025 - ABBV Stock was up 5.5%

• AbbVie's upward movement is linked to its recent FDA filing for tavapadon, a potential treatment for Parkinson's disease. This development has instilled optimism among investors regarding the drug's potential success and its future impact on AbbVie's revenues.
• Options activity suggesting a bearish outlook on AbbVie may be due to profit-taking or hedging strategies among some investors. However, this activity has not significantly affected the overall market sentiment towards the stock.
• AbbVie's efforts to diversify its product portfolio beyond Humira, its blockbuster drug, with candidates like Skyrizi and Rinvoq in the development pipeline, have contributed to positive expectations for the company's growth prospects. This has further strengthened investor confidence in AbbVie's stock.

07.00.2026 - ABBV Stock was up 5.1%

• AbbVie's price target was increased to $240 by UBS, reflecting optimism about the company's performance.
• GuruFocus forecasts a possible downside for ABBV, indicating mixed perspectives on the stock.
• The positive outlook for AbbVie's growth potential and position in the pharmaceutical sector could be driving the bullish trend.
• The stock's upward momentum may be a response to the news of the raised price target, garnering favorable investor reactions.

08.00.2026 - ABBV Stock was down 5.3%

• AbbVie's stock decreased after lowering its Q4 and full-year 2025 guidance, receiving a downgrade from Wolfe Research, and refuting acquisition discussions with Revolution Medicines. These developments likely influenced the bearish movement.
• Xilio Therapeutics raised $35.8 million through warrant exercises and met a development milestone with AbbVie, providing positive news for Xilio amidst AbbVie's challenges, potentially shifting investor focus.
• AbbVie's denial regarding Revolution Medicines acquisition rumors, following a surge in Revolution's stock, contributed to market volatility and potentially impacted AbbVie's stock decline.
• Market sentiment towards pharmaceutical companies and their strategic decisions, exemplified by the varied news on AbbVie and Revolution Medicines, may have also influenced AbbVie's stock performance today.

31.06.2025 - ABBV Stock was down 0.2%

• AbbVie reported strong Q2 sales growth and raised its 2025 earnings outlook, but the stock faced downward pressure.
• Market reaction to the company missing EPS estimates despite exceeding sales expectations may be a factor.
• Concerns about the potential impact of Humira's future decline on revenue growth, despite growth in Skyrizi and Rinvoq, are looming.
• AbbVie's stock movement may have been influenced by the overall performance of the pharmaceutical industry, with upcoming earnings releases from other key players like MRK, AZN, BMY, and MRNA.